Become a digitalPLUS subscriber. $12 for 12 weeks.
Business

Samuel D. Waksal and Erbitux

Samuel D. Waksal, founder of ImClone Systems, with vials of his company's cancer drug Erbitux. Stewart sold almost 4,000 shares of biotech drug maker ImClone a day before the U.S. Food and Drug Administration announced it will not review ImClone's application for Erbitux. Doctors in June 2003... The New York Times
Loading